For the HPLC analysis of basic compounds such as short amines, ion exchange columns
or ODS columns with an ion pair reagent are commonly used. However, for the analysis
using ODS columns with an ion pair reagent, it is problematic to control the separation
because the following two modes contribute to the separation.
1) Mode 1
With this mode, the sample and the ion pair reagent generate an ion pair
compound, and at the same time, the sample hydrophobicity increases due to
the presence of an alkyl chain coming from the ion pair reagent. Therefore
the sample is retained by the column.
R-NH3(+) + ion pair reagent(-) = [R-NH3(+)(-) ion pair reagent]
2) Mode 2
With this mode, the ODS column works as an ion exchange column. The strongly
hydrophobic alkyl chain coming from the ion pair reagent is adsorbed by the
packing material.
Compared with ODS columns, polymer-based reversed phase ODP2 HP, Asahipak ODP
and RSpak DE
series columns
have the following advantages:
a) Reversed phase analysis of short amines can be performed with an eluent at
pH10-11 without using an ion pair reagent.
b) Under alkaline conditions, the peak shapes of short amines are very
sharp.
c) ODP and DE columns are stable over a wide pH range from pH2 to pH11.
Operation Manual / Certificate of Analysis
Operation Manuals and Certificate of Analysis / Inspection Certificate for the following products can be downloaded here.
Product Name Index
- DE-213 (RSpak)
- DE-413 (RSpak)
- DE-613 (RSpak)
- ODP-50 10E (Asahipak)
- ODP-50 2D (Asahipak)
- ODP-50 4D (Asahipak)
- ODP-50 4E (Asahipak)
- ODP-50 6D (Asahipak)
- ODP-50 6E (Asahipak)
- ODP-90 20F (Asahipak)
- ODP2 HP-10E
- ODP2 HP-2B
- ODP2 HP-2D
- ODP2 HP-4B
- ODP2 HP-4D
- ODP2 HP-4E
Applications
- Basic Drugs : Under Neutral Condition
- Basic Drugs : Effects of Eluent pH
- Basic Drugs : Effects of Ion Concentration
- Effects of pH of Eluent on Elution Volume and Plate Number (ODP-50 4D)
- Antifebriles (1) (DS-613)
- Antifebriles (2) (DM-614)
- Antipyretic Analgesics (ODP-50 4D)
- Diuretics (1) (ODP-50 4D)
- Diuretics (2) (DE-613)
- Anti Cancer Drugs (ODP-50 4D)
- Drugs (ODP-50 4D)
- Anti Inflammatory Drugs (1) (ODP-50 4E)
- Anti Inflammatory Drugs (2) (ODP-50 4E)
- Scopolamine and Atropine
- Tetracaine (ODP-50 4D)
- Procainamides (1) (DE-613)
- Procainamides (2) (DE-413)
- Procaine and Procaineamide (ODP-50 4D)
- Methylxantines (1) (DS-613)
- Methylxantines (2)
- Local Anesthetics (1) (ODP-50 4D)
- Local Anesthetics (2) (DE-413)
- Cinchona Alkaloids
- Antibiotics (1) (ODP-50 4D)
- Antibiotics (2) (DE-413)
- Sulfanilamides (DE-413)
- Barbiturates (ODP-50 4D)
- Effects of pH of Eluent on Sensitivity of Barbital
- Berberine in Japanese Goldthread (ODP-50 4D)
- Glycyrrhizin in Licorice (ODP-50 6D)
- Saikosaponins (ODP-50 6D)
- Soyasaponin in Soy Bean (DS-613)
- Curative Drugs to Eradicate H.Pyrori (JJ-50 2D)
- Enalapril Maleate (DS-413)
- Tetracycline Derivative Antibiotics (ODP-40 4D)
- Short Amines (ODP2 HP)
- Ginsenoside (Ginseng Saponin) (DS-413)
- Ginsenoside (Carrot Saponin) (NH2P-50 4E)
- Analysis of Macrolide Antibiotics and Derivatives (ODP-50 4D)
- Ribavirin (KS-801)
- Anti-diabetes Drugs (NH2P-50 4E)
- LC/MS/MS Analysis of Oral Anti-diabetes Drugs (VC-50 2D)
- Characterization of Polymeric Excipients by SEC-IR (SB-806M HQ)
- Simultaneous Analysis of Multi Symptom Cold Formula (ODP2 HP)
- LC/MS Analysis of Statins (ODP2 HP-2B)
- LC/MS Analysis of Metformin (NH2P-40 2D)
- Separation of Gingerol and Shogaol (C18M 4D)
- Bibliographic Information for Analysis of Conjugate Vaccine
- LC/MS/MS Analysis of Organic Sulfonic Acids (VT-50 2D)
- Analysis of Allantoin in a Commercial Disinfectant (VG-50 4E)
- LC/MS Analysis of Aminoglycoside Antibiotics (VC-50 2D)
- LC/MS/MS Analysis of Ribavirin (VC-50 2D)
- LC/MS/MS Analysis of Salacia Extract (1) (VC-50 2D)
- LC/MS/MS Analysis of Salacia Extract (2) (VT-50 2D)
- Comparison of Analysis of Glucosamine Hydrochloride between Polymer-based Amino Columns and Silica-based Amino Columns
- LC/MS Analysis of Streptomycins (VC-50 2D)
- LC/MS/MS Analysis of Citicoline (VT-50 2D)
- SEC Analysis of Liraglutide Formulation (KW-802.5)
- SEC Analysis of Antibody Drug Conjugate (LW-803)
- SEC Analysis of Saccharated Ferric Oxide Injection (SB-804 HQ + SB-802.5 HQ)
- Analysis of α-GPC in Supplements (NH2P-50 4E)
- SEC Analysis of Rituximab (LW-803)
- Analysis of Trypsin-Digested Rituximab (C18U 2D)
- PEG-Chymotrypsin (KW-802.5)
- SEC Analysis of PEG-Asparaginase (SB-806 HQ)
- LC/MS Analysis of Macrolide Antibiotics (C18U 2B)
- SEC Analysis of Filgrastim (KW-803)
- Analysis of Levocarnitine (NH2P-50 4E)
- Analysis of Inositol According to Japanese Pharmaceutical Excipients 2018 (KS-801)
- Analysis of Sodium Risedronate (IC I-524A)
- Analysis of Ibandronate Sodium (I-524A)
- Analysis of Zoledronic Acid (IC I-524A)
- Separation of Fosfomycin and its Thermal Decomposition Products (NH2P-50 4E)
- Analysis of Semaglutide Formulation (KW-802.5)
- Analysis of Ferric Carboxymaltose (SB-804 HQ + SB-802.5 HQ)
- Quantitative Analysis of Sucrose in Saccharated Iron Oxide Injection (VG-50 4E)
- Analysis of Carboplatin (NH2P-50 4E)
- Separation of Ceftazidime and Arginine (KW402.5-4F)
- Analysis of Sorbitol in Nicardipine Hydrochloride Injection (NH2P-50 4E)
- SEC Analysis of Etelcalcetide Hydrochloride (KW-802.5)